Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort

Abstract : Purpose. Questions remain on how the excess risk of breast cancer associated with menopausal hormone therapy (MHT) evolves after treatment stops. Methods. We investigated that issue in the E3N cohort, with 3678 invasive breast cancers identified between 1992 and 2008 among 78 353 women (881 290 person-years of postmenopausal follow-up). Exposure to MHT was assessed through biennial self-administered questionnaires and classified by type of progestagen component (progesterone or dydrogesterone; other progestagen), duration (short-term ≤5 years; long-term >5 years) and time since last use (≤5, 5-10, 10+ years). Hazard ratios (HR) and confidence intervals (CI) were estimated with Cox models. Results. Among short-term users, only those currently using estrogens associated with a progestagen other than progesterone/dydrogesterone had a significantly elevated breast cancer risk (HR 1.70, 95% CI 1.50-1.91, compared with never users). Long-term use of this type of MHT was associated with a HR of 2.02 (1.81-2.26) when current and of 1.36 (1.13-1.64), 1.34 (1.04-1.73) and 1.52 (0.87-2.63) when stopped ≤5, 5-10, and 10+ years earlier, respectively. Conclusions. Our results suggest residual increases in breast cancer risk several years after MHT cessation, which are restricted to long-term treatments. Whether increases persist more than 10 years after cessation deserves continuing investigation.
Type de document :
Article dans une revue
Breast Cancer Research and Treatment, Springer Verlag, 2014, 145 (2), pp.535-43. 〈10.1007/s10549-014-2934-6〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01319982
Contributeur : Agnès Fournier <>
Soumis le : lundi 23 mai 2016 - 12:16:18
Dernière modification le : mercredi 21 mars 2018 - 18:57:40

Fichiers

Article_soumis_versionHAL (1)....
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

UPMC | UVSQ | E3N | FNCLCC | CESP | IGR

Citation

Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, et al.. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment, Springer Verlag, 2014, 145 (2), pp.535-43. 〈10.1007/s10549-014-2934-6〉. 〈inserm-01319982〉

Partager

Métriques

Consultations de la notice

241

Téléchargements de fichiers

130